Efficacy and Safety Evaluation of BCMA-UCART

Study Overview
=================
Brief Summary
-----------------
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

Detailed Description
-----------------
BCMA(B-Cell maturation antigen) is a tumor antigen of multiple myeloma. Using a genetic engineering strategy to assemble an anti-BCMA CAR(chimeric antigen receptor) in T cells will help these CART cells to recognize and kill BCMA-expressing MM tumor cells. BCMA-UCART is a kind of allogeneic CART, originating from T cells of health donors. This open-label, dose-escalation study aims to evaluate the safety and anti-tumor efficacy of BCMA-UCART in treating relapsed or refractory multiple myeloma.

Official Title
-----------------
Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Biological: BCMA-UCART


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have the capacity to give informed consent; Confirmed diagnosis of active MM as defined by NCCN and IMWG criteria; Have a diagnosis of BCMA+ multiple myeloma (MM), (≥ 5% BCMA+ in CD138+ plasma cells by flow cytometry obtained within 45 days of study enrollment); Refractory and relapsed MM patients after > 2 cycles of induction therapy,or,have relapsed or treatment refractory disease following autologous stem cell transplant (ASCT); ECOG score=0-2. Subjects according with any of the following options: Age≥50; Failure with separation of T cells during autologous CART processing; or, Failure with expansion of autologous CART; or, The proportion of T cells in PBMC <10%; or, Won't benefit from autologous CART therapy because of disease progress. Exclusion Criteria: Pregnant or nursing women; Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy Active infection, HIV infection, syphilis serology reaction positive; Active hepatitis B, hepatitis C at the time of screening Significant hepatic dysfunction as following, SGOT(serum glutamic-oxaloacetic transaminase)> 5 x upper limit of normal; bilirubin > 3.0 mg/dL; Lymphotoxic chemotherapeutic agents within 2 weeks of leukapheresis serious mental disorder; With severe cardiac, liver, renal insufficiency, diabetes and other diseases; Participate in other clinical research in the past three months; previously treatment with any gene therapy products Contraindication to cyclophosphamide or fludarabine chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Interventional Model Description: 0.5-1*10 6/KgBW, 1-2*10 6/KgBW,2-3*10 6/KgBW
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BCMA-UCART<br>Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10 6/KgBW, 1-2*10 6/KgBW,2-3*10 6/KgBW. | Biological: BCMA-UCART<br>* A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) | Proportion of patients in whom a response among complete response or partial response, as defined by International Myeloma Working group(IMWG) response criteria , will be observed. | Up to 90 days after T cell infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability | Adverse events assessed according to NCI-CTCAE v4.03 criteria | Up to 35 days after T cell infusion | 
| Duration of persistence of BCMA-UCART | Detect the duration of BCMA-UCART after injection using FACS or Q-PCR | Baseline up to 1 year |